We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
FOXO4-DRI is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most FOXO4-DRI studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2017–2025.
Based on 5 studies
Confidence
LowBy outcome
The current evidence for FOXO4-DRI is insufficient to assign an evidence score, based on 5 indexed studies. A designed senolytic peptide that disrupts the FOXO4–p53 interaction to selectively kill senescent ('zombie') cells. Honest appraisal: the landmark and follow-up evidence is entirely in mice and cell culture — there are no human trials. Sold grey-market for 'anti-aging'; research-use-only. Representative study: PMID 28340339.
The commonly studied dose of FOXO4-DRI is No validated human dose. The mouse studies used intraperitoneal regimens; grey-market self-injected 'anti-aging' dosing is anecdotal and unsupported by any human data.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Lactotripeptides
Mostly mechanism / observationalTwo milk-casein-derived tripeptides — Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) — produced by fermenting milk with Lactobacillus helveticus or hydrolysing casein. They inhibit ACE in vitro and have been studied extensively for blood pressure. Honest appraisal: multiple meta-analyses find a small, statistically-significant drop in systolic/diastolic BP, but the effect is modest, heterogeneous, larger in Japanese than Western trials, and dented by clear publication bias plus outright-null trials (e.g. the Dutch Engberink RCT).
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
FOXO4-DRI (FOXO4 D-retro-inverso senolytic peptide)
A designed senolytic peptide that disrupts the FOXO4–p53 interaction to selectively kill senescent ('zombie') cells. Honest appraisal: the landmark and follow-up evidence is entirely in mice and cell culture — there are no human trials. Sold grey-market for 'anti-aging'; research-use-only.
FOXO4-DRI's senolytic effects — including the landmark 2017 mouse study — are demonstrated only in animal models and cell culture; there are no human trials, so its anti-aging promise is preclinical-only and self-administration is unvalidated and unsafe to assume.
FOXO4-DRI is a synthetic D-retro-inverso peptide engineered to interfere with the interaction between the transcription factor FOXO4 and p53 inside senescent cells.
Senescent cells resist apoptosis partly by sequestering p53 via FOXO4; by displacing p53, FOXO4-DRI triggers apoptosis selectively in senescent cells (a 'senolytic' effect) while largely sparing healthy cells.
The landmark 2017 study in Cell showed that, in naturally aged and chemotherapy-treated mice, the peptide cleared senescent cells and restored fitness, fur density, and kidney function — a striking proof of concept that energized the longevity field.
Subsequent papers report senolytic effects in aged Leydig cells, expanded chondrocytes, senescent fibroblasts, keloids, and tumor microenvironments, again in animal models and cell culture.
The honest evidence picture is that there are no published human pharmacokinetic, efficacy, or safety trials of FOXO4-DRI; the manufacturing of a D-retro-inverso peptide is demanding, and grey-market 'FOXO4-DRI' sold for self-administered anti-aging is unverified in identity, purity, and sterility, with unknown human dosing and safety.
Clearing senescent cells also has context-dependent risks (some senescent cells aid wound healing and tumor suppression). The score reflects compelling but preclinical-only evidence with no human data.
The peptide displaces p53 from FOXO4 in senescent cells, releasing p53 to trigger apoptosis selectively in those cells.
By exploiting senescent cells' dependence on FOXO4-mediated apoptosis resistance, it kills 'zombie' cells while largely sparing healthy ones.
The D-retro-inverso design uses D-amino acids in reverse sequence to resist proteolysis and improve cell entry, but makes synthesis demanding.
How FOXO4-DRI works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated human dose. The mouse studies used intraperitoneal regimens; grey-market self-injected 'anti-aging' dosing is anecdotal and unsupported by any human data.
Can be taken without food
| Form | Type |
|---|---|
| 💊None established (research peptide) | Recommended |
A demanding-to-synthesize D-retro-inverso peptide; grey-market 'FOXO4-DRI' is sold for self-injection with unverified identity and purity.
Minimum: 4 weeks
Optimal: 8 weeks
Cycling: Not required
Note: No validated human dosing or schedule — the mouse studies used intermittent intraperitoneal regimens; no human protocol exists.
Dose-response data unavailable. The current published research for FOXO4-DRI does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Selectively clears senescent cells and restored fitness, fur, and kidney function in aged/chemo-treated mice — not shown in humans.
Improved markers of tissue function across several animal/cell models of aging and damage.
No published human trials; all evidence is animal or cell culture.
Senescent cells also support wound healing and tumor suppression; indiscriminate clearance plus unknown human dosing make self-use risky.
Avoid — no human safety data for a senolytic peptide.
Caution — clearing senescent cells can impair normal wound healing.
Research-use-only; not validated or recommended for human use.
Tip: No human safety data; senolytic clearance has context-dependent risks.
Tip: Inherent to grey-market self-injected peptides; sterility unverified.
Timing is flexible for FOXO4-DRI — consistent daily use matters more than the time of day. No validated human dosing or schedule; research-use-only peptide.
FOXO4-DRI should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are unknown human effects, injection-site reaction / infection. Use caution if any of these apply to you: Pregnancy / breastfeeding; Any non-research human use (no safety data).
HGH (Somatropin)
Mostly mechanism / observationalRecombinant human growth hormone — the classic performance and 'anti-aging' hormone. FDA-approved as a prescription injectable ONLY for growth-hormone deficiency and a handful of other conditions, where replacement reliably improves body composition. But its anti-aging and athletic reputation OUTSTRIPS the evidence: in healthy older adults and athletes, randomized trials and systematic reviews (Liu 2007/2008) show only small body-composition changes, NO functional or strength benefit, and MORE adverse events — edema, arthralgia, carpal tunnel, and impaired glucose tolerance. Distributing or using it for anti-aging or sport is illegal in the US, and it is NOT a dietary supplement. This is a gated harm-reduction reference, not a recommendation.